New vaccine aims to shield against multiple coronavirus types

NCT ID NCT07280858

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: SK Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new vaccine called GBP511, designed to protect against several sarbecoviruses (a group that includes SARS-CoV-2). About 368 healthy adults will receive one or two doses at different strengths, with or without an adjuvant to boost immune response. The goal is to check safety and how well the vaccine triggers the body's defenses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GBP511 vaccine (with or without CAS-1 adjuvant)
What this could lead to: If successful, this could lead to a vaccine that protects against multiple sarbecoviruses (like SARS-CoV-2 and related viruses), potentially reducing the need for frequent updates.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 368 participants, so safety and immune response are still being tested. The vaccine may not produce strong enough immunity or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS SARBECOVIRUS

Contacts and locations

Locations

Linear
RECRUITING

Nedlands, Western Australia, 6009, Australia
Momentum Clinical Research Darlinghurst
NOT_YET_RECRUITING

Sydney, Kent Street, 309, Level 9, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.